A Study to Assess Pharmacokinetics, Safety and Tolerability of Multiple Doses of CAT-354 in Subjects With Moderate Asthma
A Double-Blind, Placebo Controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Multiple Intravenous Doses of 3 Dose Levels of CAT-354 in Subjects With Moderate Asthma
Sponsor: MedImmune LLC
Terminated
Study recruitment was terminated before the planned number of subjects was enrolled in CAT-354 10 mg/kg group due to the slow recruitment rate.
Other terminated trials from MedImmune LLC
- TNBC - Triple-Negative Breast Cancer · Phase PHASE1 · May 2023
- Healthy Volunteers · Phase PHASE1 · May 2020
- Colorectal Neoplasms · Phase PHASE1 · Oct 2018
- CTCL · Phase PHASE1 · Oct 2018
- Respiratory Syncytial Virus · Phase PHASE2 · Nov 2016
More terminations from MedImmune LLC
Listed as NCT00974675, this PHASE1 trial focuses on Moderate Asthma and remains terminated or withdrawn. Sponsored by MedImmune LLC, it has been updated 11 times since 2006, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE1
▶ Show 6 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE1
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE1
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE1
-
Jun 2017 — Aug 2017 [monthly]
Terminated PHASE1
Status: Completed → Terminated
-
Feb 2017 — Jun 2017 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Sep 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MedImmune LLC
For direct contact, visit the study record on ClinicalTrials.gov .